Targeted cancer therapy and immunosuppression using radiolabeled monoclonal antibodiesBETHGE, Wolfgang A; SANDMAIER, Brenda M.Seminars in oncology. 2004, Vol 31, Num 1, pp 68-82, issn 0093-7754, 15 p.Article

Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: a phase II studyFEDERMANN, Birgit; BORNHAUSER, Martin; FAUL, Christoph et al.Haematologica (Roma). 2012, Vol 97, Num 10, pp 1523-1531, issn 0390-6078, 9 p.Article

Radioimmunotherapy with bismuth-213 as conditioning for nonmyeloablative allogeneic hematopoietic cell transplantation in dogs: A dose deescalation studyBETHGE, Wolfgang A; WILBUR, D. Scott; STORB, Rainer et al.Transplantation. 2004, Vol 78, Num 3, pp 352-359, issn 0041-1337, 8 p.Article

Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioningBETHGE, Wolfgang A; HEGENBART, Ute; FORMAN, Stephen J et al.Blood. 2004, Vol 103, Num 3, pp 790-795, issn 0006-4971, 6 p.Article

Selective T-cell ablation with bismuth-213-labeled anti-TCRαβ as nonmyeloablative conditioning for allogeneic canine marrow transplantationBETHGE, Wolfgang A; WILBUR, D. Scott; STORB, Rainer et al.Blood. 2003, Vol 101, Num 12, pp 5068-5075, issn 0006-4971, 8 p.Article

Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 studyBETHGE, Wolfgang A; LANGE, Thoralf; WULF, Gerald et al.Blood. 2010, Vol 116, Num 10, pp 1795-1802, issn 0006-4971, 8 p.Article

Marginal Zone B-Cell Non-Hodgkin's Lymphoma of Mucosa-Associated Lymphoid Tissue Type : Imaging FindingsMAKSIMOVIC, Olga; BETHGE, Wolfgang A; PINTOFFL, Jan P et al.American journal of roentgenology (1976). 2008, Vol 191, Num 3, pp 921-930, issn 0361-803X, 10 p.Article

Bismuth 213-labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow graftsSANDMAIER, Brenda M; BETHGE, Wolfgang A; WILBUR, D. Scott et al.Blood. 2002, Vol 100, Num 1, pp 318-326, issn 0006-4971Article

Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti―T-cell globulin ATG-FreseniusSOCIE, Gérard; SCHMOOR, Claudia; KOLBE, Karin et al.Blood. 2011, Vol 117, Num 23, pp 6375-6382, issn 0006-4971, 8 p.Article

Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantationFEUCHTINGER, Tobias; OPHERK, Kathrin; HAMPRECHT, Klaus et al.Blood. 2010, Vol 116, Num 20, pp 4360-4367, issn 0006-4971, 8 p.Article

Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioningKAHL, Christoph; STORER, Barry E; LETS, Jose F et al.Blood. 2007, Vol 110, Num 7, pp 2744-2748, issn 0006-4971, 5 p.Article